Haemonetics Statistics
Total Valuation
Haemonetics has a market cap or net worth of $3.89 billion. The enterprise value is $4.82 billion.
| Market Cap | 3.89B |
| Enterprise Value | 4.82B |
Important Dates
The next estimated earnings date is Thursday, February 5, 2026, before market open.
| Earnings Date | Feb 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Haemonetics has 46.81 million shares outstanding. The number of shares has decreased by -4.63% in one year.
| Current Share Class | 46.81M |
| Shares Outstanding | 46.81M |
| Shares Change (YoY) | -4.63% |
| Shares Change (QoQ) | -1.42% |
| Owned by Insiders (%) | 1.19% |
| Owned by Institutions (%) | 111.34% |
| Float | 46.22M |
Valuation Ratios
The trailing PE ratio is 24.16 and the forward PE ratio is 16.07. Haemonetics's PEG ratio is 1.32.
| PE Ratio | 24.16 |
| Forward PE | 16.07 |
| PS Ratio | 3.04 |
| Forward PS | 2.85 |
| PB Ratio | 4.56 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 15.21 |
| P/OCF Ratio | 13.47 |
| PEG Ratio | 1.32 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 13.38, with an EV/FCF ratio of 18.83.
| EV / Earnings | 28.67 |
| EV / Sales | 3.63 |
| EV / EBITDA | 13.38 |
| EV / EBIT | 19.08 |
| EV / FCF | 18.83 |
Financial Position
The company has a current ratio of 1.64, with a Debt / Equity ratio of 1.44.
| Current Ratio | 1.64 |
| Quick Ratio | 0.92 |
| Debt / Equity | 1.44 |
| Debt / EBITDA | 3.40 |
| Debt / FCF | 4.78 |
| Interest Coverage | 5.36 |
Financial Efficiency
Return on equity (ROE) is 19.47% and return on invested capital (ROIC) is 7.40%.
| Return on Equity (ROE) | 19.47% |
| Return on Assets (ROA) | 6.36% |
| Return on Invested Capital (ROIC) | 7.40% |
| Return on Capital Employed (ROCE) | 13.35% |
| Revenue Per Employee | $439,249 |
| Profits Per Employee | $55,637 |
| Employee Count | 3,023 |
| Asset Turnover | 0.53 |
| Inventory Turnover | 1.50 |
Taxes
In the past 12 months, Haemonetics has paid $48.92 million in taxes.
| Income Tax | 48.92M |
| Effective Tax Rate | 22.53% |
Stock Price Statistics
The stock price has increased by +5.32% in the last 52 weeks. The beta is 0.29, so Haemonetics's price volatility has been lower than the market average.
| Beta (5Y) | 0.29 |
| 52-Week Price Change | +5.32% |
| 50-Day Moving Average | 74.53 |
| 200-Day Moving Average | 65.39 |
| Relative Strength Index (RSI) | 65.90 |
| Average Volume (20 Days) | 668,307 |
Short Selling Information
The latest short interest is 3.39 million, so 7.24% of the outstanding shares have been sold short.
| Short Interest | 3.39M |
| Short Previous Month | 2.99M |
| Short % of Shares Out | 7.24% |
| Short % of Float | 7.33% |
| Short Ratio (days to cover) | 3.98 |
Income Statement
In the last 12 months, Haemonetics had revenue of $1.33 billion and earned $168.19 million in profits. Earnings per share was $3.44.
| Revenue | 1.33B |
| Gross Profit | 790.03M |
| Operating Income | 252.77M |
| Pretax Income | 217.11M |
| Net Income | 168.19M |
| EBITDA | 360.32M |
| EBIT | 252.77M |
| Earnings Per Share (EPS) | $3.44 |
Balance Sheet
The company has $297.06 million in cash and $1.23 billion in debt, with a net cash position of -$928.09 million or -$19.83 per share.
| Cash & Cash Equivalents | 297.06M |
| Total Debt | 1.23B |
| Net Cash | -928.09M |
| Net Cash Per Share | -$19.83 |
| Equity (Book Value) | 849.17M |
| Book Value Per Share | 18.17 |
| Working Capital | 351.36M |
Cash Flow
In the last 12 months, operating cash flow was $289.04 million and capital expenditures -$32.96 million, giving a free cash flow of $256.08 million.
| Operating Cash Flow | 289.04M |
| Capital Expenditures | -32.96M |
| Free Cash Flow | 256.08M |
| FCF Per Share | $5.47 |
Margins
Gross margin is 59.50%, with operating and profit margins of 19.04% and 12.67%.
| Gross Margin | 59.50% |
| Operating Margin | 19.04% |
| Pretax Margin | 16.35% |
| Profit Margin | 12.67% |
| EBITDA Margin | 27.14% |
| EBIT Margin | 19.04% |
| FCF Margin | 19.29% |
Dividends & Yields
Haemonetics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 4.63% |
| Shareholder Yield | 4.63% |
| Earnings Yield | 4.32% |
| FCF Yield | 6.58% |
Analyst Forecast
The average price target for Haemonetics is $88.38, which is 6.48% higher than the current price. The consensus rating is "Buy".
| Price Target | $88.38 |
| Price Target Difference | 6.48% |
| Analyst Consensus | Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on December 3, 2012. It was a forward split with a ratio of 2:1.
| Last Split Date | Dec 3, 2012 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
Haemonetics has an Altman Z-Score of 2.55 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.55 |
| Piotroski F-Score | 6 |